Work

Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.4_suppl.tps643

Authors: Michael J. Overman, Katherine A Guthrie, Mohamed E. Salem, Katrina Sophia Pedersen, Aparna Kalyan, Shay Bellasea, Philip Agop Philip

Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Levine Cancer Institute, Mayo Clinic, Northwestern University, Wayne State University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4205502345

Cites:

Cited by: 2

Related to: 10